Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

Inclusion Criteria: * Indication for cardiac resynchronization therapy-defibrillator (CRT-D) device implant according to the latest ESC (European Society of Cardiology) guidelines * De-novo implant of a Platinium 4LV CRT-D device (or any newer 4LV CRT-D model manufactured by MicroPort CRM) * Reviewed, signed and dated informed consent form Exclusion Criteria: * LV lead previous implant attempt * Upgrade to CRT from a previously implanted pacemaker or implantable cardioverter-defibrillator (ICD), or CRT device replacement * Known allergy to contrast media used for imaging during cardiac catheterization * Tricuspid valvular disease or any type of tricuspid replacement heart valve (mechanical or tissue) * Severe renal failure (creatinine clearance according to the Modification of Diet in Renal Disease (MDRD) formula \< 30ml/min/m²) * Active myocarditis * Stroke, myocardial infarction or cardiac revascularization within 40 days prior to implant * Previous heart transplant or currently on heart transplant list * Life expectancy less than 1 year * Already included in another clinical study that could confound the results of this study * Pre-menopausal women / women in childbearing age, including pregnant and breastfeeding women * Less than 18 years old or under guardianship * Incapacitated subject, inability to understand the purpose of the study, or to meet follow-up visits at the implanting site as defined in the protocol * Diagnosis of drug addiction (substance use disorder)